Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder

Trial Profile

Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs Apixaban (Primary)
  • Indications Thromboembolism
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 10 Nov 2017 Planned End Date changed from 30 Oct 2017 to 30 Jan 2018.
    • 10 Nov 2017 Planned primary completion date changed from 29 Oct 2017 to 29 Jan 2018.
    • 12 Apr 2016 Planned number of patients changed from 40 to 44.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top